HighPoint Advisor Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

HighPoint Advisor Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$292K	Buy	+3,538	New	+$335K	0.03%	403
2021 Q3	$376K	Buy	3,437 +128	+4%	+$13.3K	0.04%	360
2021 Q2	$310K	Buy	3,309 +405	+14%	+$37.3K	0.03%	390
2021 Q1	$266K	Buy	+2,904	New	+$245K	0.03%	393

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HighPoint Advisor Group's HZNP Position: Q2 2022 in Review

HighPoint Advisor Group opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022: 3,538 shares worth $292K. The stake represents 0.03% of the portfolio and ranks #403 among its holdings. This is a return to the name: HighPoint Advisor Group previously reported a position in HZNP as recently as Q3 2021.

HighPoint Advisor Group first reported a position in HZNP in Q1 2021 and has held it in 4 quarters since. The position peaked at $376K in Q3 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

HighPoint Advisor Group held 3,538 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $292K as of Q2 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new HighPoint Advisor Group position in Q2 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.03% of HighPoint Advisor Group's portfolio in Q2 2022, its #403 holding.
HighPoint Advisor Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and has held it in 4 quarters since.
HighPoint Advisor Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $376K in Q3 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on HighPoint Advisor Group's 13F filing for Q2 2022, filed 15 Aug 2022.